Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413 (Q46105113)

From Wikidata

Jump to navigation Jump to search

scientific article published on May 15, 2003

Language	Label	Description	Also known as
English	Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413	scientific article published on May 15, 2003

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/12743142

Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413 (English)

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

phase III clinical trial

0 references

Adaptive radiation therapy

0 references

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

author name string

Radiation Therapy Oncology Group 9413

14

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/12743142

M. Roach

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743142

1 January 2024

M. DeSilvio

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743142

1 January 2024

C. Lawton

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743142

1 January 2024

V. Uhl

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743142

1 January 2024

M. Machtay

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743142

1 January 2024

M. J. Seider

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743142

1 January 2024

M. Rotman

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743142

1 January 2024

C. Jones

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743142

1 January 2024

S. O. Asbell

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743142

1 January 2024

R. K. Valicenti

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743142

1 January 2024

S. Han

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743142

1 January 2024

C. R. Thomas

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743142

1 January 2024

W. S. Shipley

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743142

1 January 2024

language of work or name

0 references

publication date

1 May 2003

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/12743142

15 May 2003

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12743142

1 January 2024

full work available at URL

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2003.05.004

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/12743142

21

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/12743142

10

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/12743142

1904-1911

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/12743142

Radical prostatectomy or radiotherapy in carcinoma of prostate. The dilemma continues.

4

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

5

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

7

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

8

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials

9

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06

10

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer.

11

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

Lack of prostate cancer radiosensitization by androgen deprivation

13

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.

14

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer.

15

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer

16

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

The role of the urethrogram during simulation for localized prostate cancer

17

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

Nonparametric Estimation from Incomplete Observations

18

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

21

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

Practical application of biochemical failure definitions: what to do and when to do it

23

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

Considerations for monitoring and evaluating treatment effects in clinical trials.

24

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

Designs for group sequential tests.

25

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

Implications of prostate micrometastases in pelvic lymph nodes: an archival tissue study.

26

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

Prospective analysis of prostate-specific markers in pelvic lymph nodes of patients with high-risk prostate cancer

27

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer

28

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.

29

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients

30

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer

31

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy

33

1 reference

10.1200/JCO.2003.05.004

https://api.crossref.org/works/10.1200/JCO.2003.05.004

1 January 2024

Identifiers

10.1200/JCO.2003.05.004

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/12743142

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/12743142

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46105113&oldid=2184242733"